Methylfolate
L-Methylfolate (5-MTHF)
The active, bioavailable form of folate essential for mood, energy, and methylation - especially important for MTHFR variants.
L-Methylfolate (5-MTHF) is the active, bioavailable form of vitamin B9 (folate). Unlike folic acid, it doesn't require conversion by the MTHFR enzyme, making it essential for the 30-40% of people with MTHFR gene variants who cannot efficiently convert folic acid. It plays crucial roles in neurotransmitter synthesis, DNA repair, and the methylation cycle that affects energy, mood, and detoxification.
Mechanisms of Action
Methylation Support
Donates methyl groups for hundreds of biochemical reactions
Neurotransmitter Synthesis
Required for producing serotonin, dopamine, and norepinephrine
DNA Synthesis & Repair
Essential for cell division and genetic repair
Recommended Dose
400-800mcg daily
Loading: Start low (400mcg) and increase gradually; some need higher doses (1-15mg) for depression
Optimal Timing
- Morning with or without food
- Consistent daily timing
Can be taken without food
Best Form
L-Methylfolate (5-MTHF)
Alternatives: Folinic acid (for those sensitive to methylfolate), Quatrefolic (branded 5-MTHF)
Avoid folic acid if you have MTHFR variants. Look for 'L-methylfolate' or '5-MTHF' on the label.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Best taken in the morning as it can be energizing. Pair with methylcobalamin (B12) for optimal methylation support.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Improved Mood
Better emotional balance, especially in those with low folate
Increased Energy
Less fatigue, more mental clarity
Lower Homocysteine
Reduced cardiovascular risk marker
Overmethylation Symptoms
Anxiety, irritability if dose too high (especially with COMT variants)
Essential; 400-800mcg recommended for neural tube defect prevention
Especially beneficial; may need higher doses
Who Should NOT Take This
- History of bipolar disorder (may trigger mania - start very low)
- Seizure disorders (high doses)
Drug Interactions
May reduce effectiveness of methotrexate for certain conditions
May affect seizure threshold at high doses
Possible Side Effects
Tip: Reduce dose; may indicate overmethylation
Tip: Take in morning; reduce dose
Tip: Start with lower dose
Warnings
- Start low and increase gradually to avoid overmethylation
- Always pair with methylcobalamin (B12) to prevent B12 masking
- If anxiety increases, reduce dose or try folinic acid instead
B-Complex (Methylated)
complementaryB vitamins work together in methylation
Optimal methylation cycle support with all B vitamins
L-Methionine
essentialRecycles homocysteine back to methionine
Healthy methylation cycle
Myo-Inositol
complementaryOften combined for fertility support
Enhanced reproductive health and egg quality
Vitamin B12
complementaryBoth work together in methylation
Optimal methylation and homocysteine metabolism
Top studies from 40+ peer-reviewed papers
Borges-Vieira JG et al. • Nutritional neuroscience (2023)
“As for anxiety symptoms, the availability of results is limited to adjuvant vitamin D therapy.”
Key Findings:
- Systematic review examining Methylfolate efficacy
- Published in Nutritional neuroscience (2023)
- Further research warranted to confirm findings
Maruf AA et al. • Pharmacopsychiatry (2022)
“ Adjunctive L-methylfolate may have modest efficacy in antidepressant-treated adults with MDD.”
Key Findings:
- In the meta-analysis of categorical Hamilton Rating Scale for Depression-17 response, (three studies, N=483) adjunctive L-methylfolate was associated with a small effect versus antidepressant monotherapy (relative risk: 1.25, 95% confidence interval [CI]=1.08 to 1.46, p=0.004).
- A meta-analysis of four studies (N=507) using a continuous measure of depressive symptoms showed a similar effect of adjunctive L-methylfolate (standardized mean difference=- 0.38, 95% CI=- 0.59 to-0.17, p=0.0003).
- Adjunctive L-methylfolate may have modest efficacy in antidepressant-treated adults with MDD.
Sakuma K et al. • Psychopharmacology (2018)
“Our findings suggest that pooled FA + AP treatment improves negative symptoms in schizophrenia patients.”
Key Findings:
- Pooled FA + AP treatments were more effective than placebo + AP for negative symptoms (N = 5, n = 281; SMD = -0.25, 95% CI = -0.49, -0.01, p = 0.04, I2 = 0%).
- Our findings suggest that pooled FA + AP treatment improves negative symptoms in schizophrenia patients.
- Moreover, this treatment was well tolerated.
- However, because our results might exhibit a small-study effect, future studies with a larger sample should be conducted to obtain more robust results.
Andras A et al. • The Cochrane database of systematic reviews (2013)
“Currently, no recommendation can be made regarding the value of treatment of hyperhomocysteinaemia in peripheral arterial disease.”
Key Findings:
- Currently, no recommendation can be made regarding the value of treatment of hyperhomocysteinaemia in peripheral arterial disease.
- Further, well constructed trials are urgently required.
- Further research warranted to confirm findings
Papakostas GI et al. • American Journal of Psychiatry (2012)
“L-methylfolate at 15mg/day significantly improved outcomes in patients with SSRI-resistant depression.”
Key Findings:
- Effective adjunct for treatment-resistant depression
- Significant improvement over placebo
- Well-tolerated at high doses
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.